Mastek Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2025, 9:09 am

Competitors of Mastek Ltd

All Competitor Stocks of Mastek Ltd

Quarterly Result

Last Updated: August 1, 2025, 5:20 pm

Below is a detailed analysis of the quarterly data for Mastek Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 915.00 Cr.. The value appears strong and on an upward trend. It has increased from 905.00 Cr. (Mar 2025) to 915.00 Cr., marking an increase of 10.00 Cr..
• For Expenses, as of Jun 2025, the value is 777.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 767.00 Cr. (Mar 2025) to 777.00 Cr., marking an increase of 10.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 137.00 Cr.. The value appears to be declining and may need further review. It has decreased from 139.00 Cr. (Mar 2025) to 137.00 Cr., marking a decrease of 2.00 Cr..
• For OPM %, as of Jun 2025, the value is 15.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00%.
• For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from -5.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 16.00 Cr..
• For Interest, as of Jun 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 18.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 19.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 106.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 15.00 Cr..
• For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 24.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 92.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 11.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 29.75. The value appears strong and on an upward trend. It has increased from 26.20 (Mar 2025) to 29.75, marking an increase of 3.55.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:53 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: November 9, 2025, 2:29 pm

Below is a detailed analysis of the balance sheet data for Mastek Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
• For Reserves, as of Sep 2025, the value is 2,661.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,447.00 Cr. (Mar 2025) to 2,661.00 Cr., marking an increase of 214.00 Cr..
• For Borrowings, as of Sep 2025, the value is 544.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 583.00 Cr. (Mar 2025) to 544.00 Cr., marking a decrease of 39.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 813.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 803.00 Cr. (Mar 2025) to 813.00 Cr., marking an increase of 10.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 4,034.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,848.00 Cr. (Mar 2025) to 4,034.00 Cr., marking an increase of 186.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 1,846.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,818.00 Cr. (Mar 2025) to 1,846.00 Cr., marking an increase of 28.00 Cr..
• For CWIP, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
• For Investments, as of Sep 2025, the value is 188.00 Cr.. The value appears strong and on an upward trend. It has increased from 178.00 Cr. (Mar 2025) to 188.00 Cr., marking an increase of 10.00 Cr..
• For Other Assets, as of Sep 2025, the value is 1,998.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,851.00 Cr. (Mar 2025) to 1,998.00 Cr., marking an increase of 147.00 Cr..
• For Total Assets, as of Sep 2025, the value is 4,034.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,848.00 Cr. (Mar 2025) to 4,034.00 Cr., marking an increase of 186.00 Cr..

Notably, the Reserves (2,661.00 Cr.) exceed the Borrowings (544.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Mastek Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 121.78. This value is within the healthy range. It has increased from 98.01 (Mar 24) to 121.78, marking an increase of 23.77.
• For Diluted EPS (Rs.), as of Mar 25, the value is 120.65. This value is within the healthy range. It has increased from 97.25 (Mar 24) to 120.65, marking an increase of 23.40.
• For Cash EPS (Rs.), as of Mar 25, the value is 145.78. This value is within the healthy range. It has increased from 129.99 (Mar 24) to 145.78, marking an increase of 15.79.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 795.84. It has increased from 676.85 (Mar 24) to 795.84, marking an increase of 118.99.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 795.84. It has increased from 676.85 (Mar 24) to 795.84, marking an increase of 118.99.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,116.75. It has increased from 990.53 (Mar 24) to 1,116.75, marking an increase of 126.22.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 183.82. This value is within the healthy range. It has increased from 170.13 (Mar 24) to 183.82, marking an increase of 13.69.
• For PBIT / Share (Rs.), as of Mar 25, the value is 159.54. This value is within the healthy range. It has increased from 140.98 (Mar 24) to 159.54, marking an increase of 18.56.
• For PBT / Share (Rs.), as of Mar 25, the value is 148.40. This value is within the healthy range. It has increased from 125.22 (Mar 24) to 148.40, marking an increase of 23.18.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 121.50. This value is within the healthy range. It has increased from 100.83 (Mar 24) to 121.50, marking an increase of 20.67.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 121.50. This value is within the healthy range. It has increased from 97.37 (Mar 24) to 121.50, marking an increase of 24.13.
• For PBDIT Margin (%), as of Mar 25, the value is 16.45. This value is within the healthy range. It has decreased from 17.17 (Mar 24) to 16.45, marking a decrease of 0.72.
• For PBIT Margin (%), as of Mar 25, the value is 14.28. This value is within the healthy range. It has increased from 14.23 (Mar 24) to 14.28, marking an increase of 0.05.
• For PBT Margin (%), as of Mar 25, the value is 13.28. This value is within the healthy range. It has increased from 12.64 (Mar 24) to 13.28, marking an increase of 0.64.
• For Net Profit Margin (%), as of Mar 25, the value is 10.88. This value exceeds the healthy maximum of 10. It has increased from 10.17 (Mar 24) to 10.88, marking an increase of 0.71.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.88. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 10.88, marking an increase of 1.05.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.26. This value is within the healthy range. It has increased from 14.38 (Mar 24) to 15.26, marking an increase of 0.88.
• For Return on Capital Employeed (%), as of Mar 25, the value is 16.88. This value is within the healthy range. It has increased from 16.75 (Mar 24) to 16.88, marking an increase of 0.13.
• For Return On Assets (%), as of Mar 25, the value is 9.73. This value is within the healthy range. It has increased from 8.14 (Mar 24) to 9.73, marking an increase of 1.59.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.15. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.15.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.22. This value is within the healthy range. It has decreased from 0.23 (Mar 24) to 0.22, marking a decrease of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.91. It has increased from 0.89 (Mar 24) to 0.91, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.95, marking an increase of 0.53.
• For Quick Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.95, marking an increase of 0.53.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 15.60. This value is below the healthy minimum of 20. It has decreased from 19.39 (Mar 24) to 15.60, marking a decrease of 3.79.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.00. This value is below the healthy minimum of 20. It has decreased from 14.92 (Mar 24) to 13.00, marking a decrease of 1.92.
• For Earning Retention Ratio (%), as of Mar 25, the value is 84.40. This value exceeds the healthy maximum of 70. It has increased from 80.61 (Mar 24) to 84.40, marking an increase of 3.79.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 87.00. This value exceeds the healthy maximum of 70. It has increased from 85.08 (Mar 24) to 87.00, marking an increase of 1.92.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 13.52. This value is within the healthy range. It has increased from 11.80 (Mar 24) to 13.52, marking an increase of 1.72.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.76. This value is within the healthy range. It has increased from 8.09 (Mar 24) to 9.76, marking an increase of 1.67.
• For Enterprise Value (Cr.), as of Mar 25, the value is 6,839.86. It has decreased from 7,924.50 (Mar 24) to 6,839.86, marking a decrease of 1,084.64.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 2.59 (Mar 24) to 1.98, marking a decrease of 0.61.
• For EV / EBITDA (X), as of Mar 25, the value is 12.03. This value is within the healthy range. It has decreased from 15.10 (Mar 24) to 12.03, marking a decrease of 3.07.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has decreased from 2.56 (Mar 24) to 1.95, marking a decrease of 0.61.
• For Retention Ratios (%), as of Mar 25, the value is 84.39. This value exceeds the healthy maximum of 70. It has increased from 80.60 (Mar 24) to 84.39, marking an increase of 3.79.
• For Price / BV (X), as of Mar 25, the value is 2.74. This value is within the healthy range. It has decreased from 3.75 (Mar 24) to 2.74, marking a decrease of 1.01.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has decreased from 2.56 (Mar 24) to 1.95, marking a decrease of 0.61.
• For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness